Monopar Therapeutics (MNPR) Insider Buying
Every C-suite and executive open-market purchase of Monopar Therapeutics stock we've tracked from SEC Form 4 filings — each scored on our six-factor model. Not financial advice.
| Ticker | Insider | Role | Value | Filed | Signal | Score |
|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Vu Quan Anh | Chief Financial Officer | $104,925 | Dec 29, 2025 | WATCH | 58 |
What this page tracks
This is a live record of open-market stock purchases by directors and officers of Monopar Therapeutics, sourced directly from SEC EDGAR Form 4 filings. We only count open-market buys — not option exercises or grants — because a personal-money purchase is the cleanest insider conviction signal.
Each filing is scored with our six-factor methodology (fundamentals, financials, technicals, conviction, CEO history, and cluster activity). See how the resulting signals performed against the S&P 500 on the track record, or browse this week's insider buys and the full signal screener.
Get new MNPR signals the morning they file
One email a day with newly scored CEO insider-buying signals. $3.99/mo, cancel anytime.
Start Free 7-Day Trial